FOLH1 and prostate carcinoma: PSMA has emerged as a promising protein target for prostate cancer for both diagnosis and therapeutic purposes (e.g., radionuclide-based therapy or other therapeutic strategies including immunotoxins, immune cells retargeting, prodrug activation, PSMA vaccines, plasmid DNA, and adenoviral immunizations.30-32 This mechanism leads to the internalization of radionuclides into the cancer cells and eventually causes cell death33 as shown in Figure 2.